Clinical Trials Logo
  1. Home
  2. Other
  3. NCT05488626

Daily Adaptive Radiation Therapy: An Individualized Approach for Stage III Lung Cancer — ARTIA-Lung  

Stage III Non-small Cell Lung Cancer Clinical Trial

Official title:
Daily Adaptive vs Non-Adaptive External Beam Radiation Therapy With Concurrent Chemotherapy for Locally Advanced Non-Small Cell Lung Cancer: A Prospective Randomized Trial of an Individualized Approach for Toxicity Reduction (ARTIA-Lung)

Clinical Trial Summary

This is a prospective multi-center randomized clinical trial designed to demonstrate that daily online adaptive radiotherapy with concomitant chemotherapy for stage III non-small cell lung cancer (NSCLC) will result in decreased acute respiratory and esophageal toxicity compared with non-adaptive radiotherapy with concomitant chemotherapy. The timepoint for this assessment will be 1 month following the end of radiotherapy and will use the Patient Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05488626
Study type Interventional
Source Varian, a Siemens Healthineers Company
Contact
Status Active, not recruiting
Phase N/A
Start date October 20, 2022
Completion date December 2025
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT02076282 - MRI Optimization Study in Stage III NSCLC N/A
Terminated NCT01577212 - Individualized Dose Prescription in Advanced Stage Lung Cancer Patients Using Modern (Chemo)Radiotherapy Phase 2
Withdrawn NCT01336543 - Consolidation Chemotherapy/Concurrent Chemo-radiotherapy for Inoperable Stage III Non-small Cell Lung Cancer (NSCLC) Phase 2
Completed NCT01102231 - Chemoradiotherapy in Stage III Non-small Cell Lung Cancer (NSCLC) Phase 2
Completed NCT00019006 - Vaccine Therapy in Treating Patients With Colon, Pancreatic, or Lung Cancer Phase 1
Recruiting NCT06082492 - The Beneficial Value of PET/CT in the Follow-up of Stage III Non-small Cell Lung Cancer Patients N/A
Active, not recruiting NCT03049618 - Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475 Phase 2
Recruiting NCT03077854 - Image-Guided Functional Lung Avoidance Thoracic Radiotherapy for Lung Cancer: A Single-Blind Randomized Trial N/A
Recruiting NCT05157542 - Neoadjuvant LDRT Combined With Durvalumab in Potentially Resectable Stage III NSCLC Phase 1
Recruiting NCT00938418 - Hypofractionated Intensity Modulated Chemoradiotherapy to Treat Locally Advanced Non-Small Cell Lung Cancer Phase 2
Recruiting NCT05361174 - A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer Phase 1/Phase 2
Active, not recruiting NCT03048500 - Nivolumab and Metformin Hydrochloride in Treating Patients With Stage III-IV Non-small Cell Lung Cancer That Cannot Be Removed by Surgery Phase 2
Not yet recruiting NCT05891080 - Neoadjuvant Therapy With Toripalimab and JS004 Combined With Platinum-based Doublet Chemotherapy for Resectable or Potentially Resectable Stage III Non-small Cell Lung Cancer: A Randomised Controlled, Open-label, Phase 2 Trial Phase 2
Active, not recruiting NCT01948141 - Nintedanib in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Up to Two Previous Chemotherapy Regimens Phase 2
Completed NCT01282437 - Prophylactic Cranial Irradiation (PCI) vs Observation in Stage III NSCLC Phase 3
Recruiting NCT05631574 - Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer Phase 1
Recruiting NCT05157503 - Treatment of Patients With Stage III Non-small Cell Lung Cancer in Russia"
Recruiting NCT05468242 - Study of Tislelizumab for Locally Advanced Non-Small Cell Lung Cancer Following Neoadjuvant Chemotherapy Plus Tislelizumab ± Bevacizumab and Definitive Concurrent Chemoradiation Therapy Phase 2
Active, not recruiting NCT06102057 - PACCELIO - FDG-PET Based Small Volume Accelerated Immuno Chemoradiotherapy in Locally Advanced NSCLC Phase 2
Recruiting NCT04984148 - Construction of CT Radiomics Model for Predicting the Efficacy of Immunotherapy in Patients With Stage III NSCLC